30 results match your criteria ntg patches

  • Page 1 of 1

[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.

Eur J Nucl Med Mol Imaging 2017 Jan 6;44(1):8-16. Epub 2016 Sep 6.

Department of Pulmonology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Netherlands.

Purpose: Nitroglycerin (NTG) is a vasodilating drug, which increases tumor blood flow and consequently decreases hypoxia. Therefore, changes in [18F] fluorodeoxyglucose positron emission tomography ([18F]FDG PET) uptake pattern may occur. In this analysis, we investigated the feasibility of [18F]FDG PET for response assessment to paclitaxel-carboplatin-bevacizumab (PCB) treatment with and without NTG patches. Read More

View Article and Full-Text PDF
January 2017

The effect of transdermal nitroglycerin on pain control in diabetic patients with peripheral neuropathy.

J Diabetes Metab Disord 2015 1;14:86. Epub 2015 Dec 1.

Emergency Disaster Center of Ministry of Health and Medical Education, Tehran, Iran.

Background: Despite high prevalence of diabetic peripheral neuropathy there is no definite treatment for the condition. The present study was conducted to assess the efficacy of transdermal nitroglycerin patch in pain control of patients with DPN.

Methods: This randomized, double-blind, crossover study was conducted on 30 patients with symmetric distal peripheral neuropathy and good glycemic control. Read More

View Article and Full-Text PDF
December 2015

A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.

Ann Oncol 2015 Nov 7;26(11):2286-93. Epub 2015 Sep 7.

Department of Respiratory Disease, Amphia Hospital, Breda Department of Respiratory Disease, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Background: Nitroglycerin (NTG) increases tumor blood flow and oxygenation by inhibiting hypoxia-inducible-factor (HIF)-1. A randomized phase II study has shown improved outcome when NTG patches were added to vinorelbine/cisplatin in patients with advanced nonsmall-cell lung cancer (NSCLC). In addition, there is evidence that the combination of bevacizumab and HIF-1 inhibitors increases antitumor activity. Read More

View Article and Full-Text PDF
November 2015

Phase I dose escalation trial of nitroglycerin in addition to 5-fluorouracil and radiation therapy for neoadjuvant treatment of operable rectal cancer.

Surgery 2015 Aug 9;158(2):460-5. Epub 2015 May 9.

VA North Texas Health Care System Department of Hematology Oncology, Radiation Oncology, and Surgery/University of Texas Southwestern, Department of Surgery and Radiation Oncology, Dallas, TX. Electronic address:

Background: Nitric oxide donors decreased cell survival in vitro and tumor load in vivo in models of rectal cancer subjected to ionizing radiation. Nitroglycerin (NTG) transdermal patches, added to chemotherapy, have been shown to improve outcomes in lung cancer patients.

Methods: This open-label, nonrandomized, multicohort, dose escalation, phase I trial had a primary endpoint to evaluate the safety, tolerability, feasibility, dose-limiting toxicity and maximum tolerated dose of topical NTG in addition to 5-fluorouracil and radiation therapy for neoadjuvant treatment of locoregionally advanced operable rectal cancer. Read More

View Article and Full-Text PDF

Transdermal nitroglycerin as an adjuvant to patient-controlled morphine analgesia after total knee arthroplasty.

Pain Res Manag 2009 Mar-Apr;14(2):109-12

Department of Anesthesia, Rabin Medical Center, Beilinson Campus, Petach Tiqvah, Israel.

Background: Nitroglycerin (NTG) has been shown to be a useful adjunct for pain treatment without increasing adverse side effects. The effects of NTG on postoperative morphine consumption after knee replacement were evaluated.

Methods: After undergoing total knee replacement, patients receiving patient-controlled morphine analgesia were randomly assigned to receive either an NTG or a placebo patch. Read More

View Article and Full-Text PDF

Effect of pioglitazone on nitroglycerin-induced impairment of nitric oxide bioavailability by a catheter-type nitric oxide sensor.

Circ J 2008 Jun;72(6):998-1002

Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.

Background: We examined whether nitroglycerin (NTG)-induced impairment of nitric oxide (NO) bioavailability could be modified by a peroxisome proliferator-activated receptor (PPAR) gammaagonist.

Methods And Results: Male New Zealand White rabbits were treated for 7 days with NTG patches, either alone or in combination with pioglitazone. Plasma NO concentration was measured with the catheter-type NO sensor located in the aorta. Read More

View Article and Full-Text PDF

Evaluation of pharmacological modulation of nitroglycerin-induced impairment of nitric oxide bioavailability by a catheter-type nitric oxide sensor.

Circ J 2007 Sep;71(9):1473-9

Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.

Background: The present study aimed to elucidate the effect of long-term treatment with nitroglycerin (NTG) on the bioavailability of nitric oxide (NO) examined by a catheter-type NO sensor. The study also examined whether these effects could be modified by an antioxidant, an angiotensin converting enzyme inhibitor, or an angiotensin II type 1 receptor antagonist (ARB).

Methods And Results: Male New Zealand rabbits were treated for 7 days with NTG patches, either alone or in combination with tempol, enalapril, or valsartan (ARB). Read More

View Article and Full-Text PDF
September 2007

Effects of topical nitroglycerine patches and ointment on digital venous plasma nitric oxide concentrations and digital blood flow in healthy conscious horses.

Vet Surg 2005 Nov-Dec;34(6):604-9

Equine Health Studies Program, Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 708033, USA.

Objective: To measure and compare palmar digital venous plasma nitric oxide (NO) concentrations and digital arterial blood flow after application of topical nitroglycerine (NTG).

Study Design: Experimental study.

Animals: Healthy adult horses (n=8). Read More

View Article and Full-Text PDF

Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits.

J Am Coll Cardiol 2002 Oct;40(7):1356-63

Division of Cardiology, University Hospital Eppendorf, Hamburg, Germany.

Objective: With the present studies we sought to determine how treatment with nitroglycerin (NTG) affects endothelial function, oxidative stress and nitric oxide (NO)-downstream signaling in Watanabe heritable hyperlipidemic rabbits (WHHL).

Background: In vitro experiments have demonstrated potent antiatherosclerotic effects of NO suggesting that treatment with NO-donors such as NTG could compensate for the diminished availability of endothelial NO. Nitric oxide may, however, not only be scavenged by reaction with endothelium-derived superoxide but also form the potent oxidant and inhibitor of vascular function, peroxynitrite (ONOO(-)). Read More

View Article and Full-Text PDF
October 2002

Nitroglycerin induces late preconditioning against myocardial infarction in conscious rabbits despite development of nitrate tolerance.

Circulation 2001 Aug;104(6):694-9

Experimental Research Laboratory, Division of Cardiology, University of Louisville and Jewish Hospital Heart and Lung Institute, Louisville, KY, USA.

Background: Recent studies suggest that the late phase of ischemic preconditioning (PC) can be mimicked by pretreatment with NO donors. The ability of clinically relevant NO donors to induce PC against infarction, however, has not been evaluated. Furthermore, it is unknown whether tolerance to the hemodynamic actions of nitrates also extends to their PC effects. Read More

View Article and Full-Text PDF

Evaluation of adhesive properties of transdermal therapeutic systems containing nitroglycerin.

Boll Chim Farm 2001 Mar-Apr;140(2):63-7

Istituto di Chimica Farmaceutica e Tossicologica, Università degli Studi di Milano, Italia.

The patch performances and the success of the transdermal drug delivery can be significantly affected by the quality of contact between the patch and the skin. Poor adhesion will dramatically reduce percutaneous delivery. In this study the adhesive properties (peel force and creep resistance) of three monolayer self-adhesive nitroglycerin (NTG) patches available on the market, Deponit, Minitran, and Triniplas, were compared. Read More

View Article and Full-Text PDF

Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta.

Circulation 2001 May;103(17):2188-94

University Hospital Eppendorf, Division of Cardiology, Hamburg, Germany.

Background: Chronic in vivo treatment with nitroglycerin (NTG) induces tolerance to nitrates and cross-tolerance to nitrovasodilators and endothelium-derived nitric oxide (NO). We previously identified increased vascular superoxide formation and reduced NO bioavailability as one causal mechanism. It is still controversial whether intracellular downstream signaling to nitrovasodilator-derived NO is affected as well. Read More

View Article and Full-Text PDF

Effects of transdermal nitroglycerin in children with congestive heart failure: a Doppler echocardiographic study.

Pediatr Cardiol 2001 Jan-Feb;22(1):11-3

Department of Pediatric Cardiology, Hôpital Cardiologique, F59037, Lille, France

The aim of this study was to evaluate by Doppler echocardiography whether administration of transdermal nitroglycerin (NTG) to children with congestive heart failure could modify mitral flow velocity profile with redistribution of left ventricular filling to late diastole, suggesting preload reduction of the left ventricle. Twelve children with congestive heart failure, aged from 6 months to 6 years (2.83 +/- 2. Read More

View Article and Full-Text PDF

Nitroglycerin rebound associated with vascular, rather than platelet, hypersensitivity.

Authors:
D Hébert J Y Lam

J Am Coll Cardiol 2000 Dec;36(7):2311-6

Department of Medicine, Montreal Heart Institute, University of Montreal Medical School, Quebec, Canada.

Objectives: The purpose of this study was to determine whether acute withdrawal of nitroglycerin (NTG) during hemodynamic tolerance is associated with platelet hypersensitivity.

Background: Nitroglycerin is an effective antianginal medication but its use is limited by the development of tolerance and rebound. We have previously demonstrated a sustained inhibition of platelet function during continued use of NTG, but whether cessation of NTG is associated with an increase in platelet function that may contribute to rebound is unknown. Read More

View Article and Full-Text PDF
December 2000

Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production.

J Am Coll Cardiol 2000 Aug;36(2):628-34

Division of Cardiology, University Hospital Eppendorf, Hamburg, Germany.

Objectives: In the present study, we tested whether a nitrate-free interval is able to prevent increases in vascular superoxide (O2*-) and the development of hypersensitivity to vasoconstrictors and whether this may result in restoration of vascular nitroglycerin (NTG) sensitivity.

Background: Intermittent NTG-patch treatment (12 h patch on/patch-off) has been shown to increase ischemic periods in patients with stable coronary arteries, suggesting a rebound-like situation during the patch-off period. Recently, we demonstrated that long-term treatment with NTG induces tolerance, which was in part related to increases in vascular O2*- and increased vasoconstrictor sensitivity. Read More

View Article and Full-Text PDF

Evidence for a causal role of the renin-angiotensin system in nitrate tolerance.

Circulation 1999 Jun;99(24):3181-7

Department of Medicine, Emory University School of Medicine, Veterans Administration Hospital, Atlanta, GA, USA.

Background: We have previously shown that nitroglycerin (NTG) therapy increases vascular expression of endothelin 1 (ET-1) and stimulates vascular superoxide (O2.-) production via activation of NADH/NADPH oxidases. Both phenomena are stimulated by angiotensin II in vitro, and the renin-angiotensin system is activated during early nitrate therapy. Read More

View Article and Full-Text PDF

Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial.

Circulation 1998 May;97(20):2017-24

Baylor College of Medicine, Houston, Tex, USA.

Background: Nitrates are widely used in the treatment of angina in patients with acute myocardial infarction (AMI). Short-term administration prevents left ventricular (LV) dilation and infarct expansion. However, little information is available regarding their long-term effects on LV remodeling in patients surviving Q-wave AMI. Read More

View Article and Full-Text PDF

Successful treatment of shoulder pain syndrome due to supraspinatus tendinitis with transdermal nitroglycerin. A double blind study.

Pain 1996 Jul;66(1):63-67

Department of Medicine, Hospital Universitario Valdecilla, Universidad de Cantabria,Santander,Spain Rehabilitatation Unit, Hospital Universitario Valdecilla, Universidad de Cantabria,Santander,Spain.

We have conducted a prospective double blind randomized and placebo controlled clinical study in 20 patients with shoulder pain syndrome caused by supraspinatus tendinitis to determine whether transdermal nitroglycerin (NTG) has analgesic action in this condition. In a randomized manner we used a 5-mg NTG (Nitroplast) patch per day over 3 days or similar placebo patches applied in the most painful area. Patients were evaluated before treatment was initiated and after 24 and 48 h. Read More

View Article and Full-Text PDF

Prevention of nitroglycerin tolerance with diuretics.

Am Heart J 1995 Sep;130(3 Pt 1):522-7

Department of Medicine, George Washington University, Washington, DC 20037, USA.

Tolerance to prolonged nitroglycerin (NTG) may be due to drug-induced intravascular expansion. To test the hypothesis that concomitant diuretics may reduce volume expansions and thus prevent NTG tolerance, we studied 23 healthy volunteers randomized to hydrochlorthiazide or placebo before and during 74-hour continuous NTG exposure. Venodilator response to NTG was tested serially with venous forearm plethysmography. Read More

View Article and Full-Text PDF
September 1995

Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance.

J Clin Invest 1995 Jan;95(1):187-94

Department of Medicine, Emory University School of Medicine, Atlanta Veterans Administration Medical Center, Georgia 30322.

We sought to examine mechanisms underlying nitroglycerin (NTG) tolerance and "cross-tolerance" to other nitrovasodilators. Rabbits were treated for 3 d with NTG patches (0.4 mg/h) and their aortic segments studied in organ chambers. Read More

View Article and Full-Text PDF
January 1995

Ointments and transdermal nitroglycerin patches for stable angina pectoris.

Cardiovasc Drugs Ther 1994 Aug;8(4):625-33

Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73104.

Nitroglycerin (NTG) ointment is used for the prophylaxis against angina pectoris, but there are no data to support its effectiveness during long-term therapy. Continuous, once-daily application of isosorbide dinitrate cream produces tolerance with complete loss of efficacy within 1 week. Nitroglycerin patches are very popular and continuous once-daily application is still claimed by some investigators to provide 24 hour antiischemic and antianginal efficacy. Read More

View Article and Full-Text PDF

Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: a comparison with a continuous schedule.

Eur Heart J 1989 Nov;10(11):998-1002

Department of Cardiology, Niguarda Hospital, Milan, Italy.

The aim of this study was to investigate nitrate tolerance during continuous treatment with nitroglycerin patches (NTG) as monotherapy, and to assess whether tolerance might be prevented by an overnight nitrate-free interval. Ten male patients, of mean age 53.2 years (range 41-62 years), with pathological coronary angiography and stable exercise-induced angina pectoris took part in a double-blind crossover study (two 15-day periods), during which the continuous and intermittent (12-h nitrate-free interval) application of NTG 20 mg (24 h)-1 patches were compared. Read More

View Article and Full-Text PDF
November 1989

Responsiveness of peripheral veins to transdermal and sublingual nitroglycerin in healthy male volunteers.

J Cardiovasc Pharmacol 1989 Oct;14(4):534-41

Division of Clinical Pharmacology, Stanford University, California.

Nitroglycerin (NTG) is a potent vascular smooth muscle relaxant. With the widespread use of transdermal NTG patches for the prophylaxis of angina, two important issues have arisen: (a) the relative efficacy of transdermal NTG patches compared to other formulations of NTG, and (b) the possibility of development of tolerance to transdermal NTG. We have investigated these two issues by studying the effect of systemically administered NTG (transdermal patches, ointment, and sublingual tablets) on alpha-adrenergic receptor agonist-mediated constriction of human dorsal hand veins. Read More

View Article and Full-Text PDF
October 1989

Transdermal nitroglycerin in angina pectoris.

Authors:
J Abrams

Eur Heart J 1989 May;10 Suppl A:11-9

Division of Cardiology, University of New Mexico School of Medicine, Albuquerque.

The transdermal nitroglycerin patches have been very successful nitrate formulations since their introduction in 1982. Nevertheless, considerable controversy regarding efficacy and tolerance has arisen. Nitroglycerin has multiple mechanisms of action in angina pectoris. Read More

View Article and Full-Text PDF

Relation of transdermal nitroglycerin efficacy with dosage in different subsets of patients.

Authors:
D E Rezaković

Am J Cardiol 1988 Mar;61(9):59E-69E

Department of Medicine, University Hospital, Faculty of Medicine, University of Zagreb, Yugoslavia.

Two single-blind placebo-controlled studies were consecutively performed with nitroglycerin (NTG) (5 and 10 mg/24 hours) patches in 24 patients with stable angina pectoris. The relation of NTG patch efficacy with dosage and different subsets of patients during acute and chronic patch therapy was analyzed. NTG patch effects were assessed by multistage treadmill exercise test at 5, 16, 20 and 24 hours after patch application, during single patch administration and after 3 months of continuous therapy, with washout phases as well as with 1- and 7-day placebo patch periods. Read More

View Article and Full-Text PDF

Acute and sustained antianginal effects of nitroglycerin patches: objective evaluation with training-effect-eliminated exercise performance index.

Am J Cardiol 1988 Mar;61(9):39E-43E

Institute of Cardiology, University of Istanbul, Turkey.

A randomized within-patient double-blind acute and sustained study was performed to compare transdermal nitroglycerin (NTG) patches (5 and 10 mg) and matching placebo in 10 patients with chronic stable angina pectoris confirmed on exercise thallium scintigraphy or coronary angiography, or both. Patients performed treadmill tests 2 and 24 hours after application of patches on the first and last days of each of the 3 treatment periods. Effects caused by sequence of treatments and training with serial testing were prominent so the changes in the well-known parameters did not favor either of the active doses over placebo. Read More

View Article and Full-Text PDF

When does nitrate tolerance develop? What dosages and which intervals are necessary to ensure maintained effectiveness?

Eur Heart J 1988 Jan;9 Suppl A:63-72

Department of Cardiology, German Heart Center, Munich.

To address the issues of tolerance development and its circumvention during long-term treatment with nitrates, several controlled studies have been performed. In patients with coronary artery disease, during long-term treatment with isosorbide dinitrate (ISDN) in sustained-release form at dosages of 20 mg t.i. Read More

View Article and Full-Text PDF
January 1988

Acute and chronic efficacy of low-dose nitroglycerin patches in stable angina pectoris.

Z Kardiol 1986 ;75 Suppl 3:90-5

In a single-blind placebo controlled study, acute and chronic efficacy of low-dose nitroglycerin patches (NTG 5 mg/day) was studied in 24 patients with stable angina pectoris. NTG patch effects were evaluated by means of the multistage treadmill exercise test. During the acute study one exercise test was carried out after the wash-out period, after placebo patch (5 hours after application) and NTG patch (5, 16, 20 and 24 hours after application), so that a 3 day wash-out period had preceded each exercise test. Read More

View Article and Full-Text PDF
February 1987

Hemodynamic and hormonal effects of high-dose transdermal nitroglycerin in patients with chronic congestive heart failure.

Am J Cardiol 1985 Sep;56(8):555-9

The hemodynamic effect of a large dose of nitroglycerin (NTG) (90 mg) given transdermally using a reservoir system was studied in 10 patients with severe, long-standing congestive heart failure. Serial hemodynamic measurements over 24 hours revealed a mild decrease in mean pulmonary artery wedge pressure. However, the change from baseline was significant only at 2 hours (19 +/- 9 vs 27 +/- 6 mm Hg). Read More

View Article and Full-Text PDF
September 1985

Antianginal effects of nitroglycerin patches.

Am J Cardiol 1984 Jul;54(1):1-7

Nitroglycerin (NTG) patches provide potentially therapeutic NTG blood levels for 24 hours, but their effects on exercise tolerance (ExT) in patients with angina have not been well characterized. Therefore, blinded, randomized trials were performed of the acute effects of both low-dose and maximal-tolerated-dose NTG patches and placebo on ExT in 14 patients with coronary artery disease and typical exertional angina. The bicycle exercise protocol of the National Institutes of Health was used and sublingual NTG administered as a positive control. Read More

View Article and Full-Text PDF
  • Page 1 of 1